All News

Researchers found that caregivers have their own concerns and issues when their loved one is transitioning from being a patient in active treatment to a cancer survivor.

Opdivo was granted an accelerated approval for a subset of patients with urothelial carcinoma.

After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.

John P. Leonard, M.D. spoke with CURE about some upcoming advancements in the treatment of follicular lymphoma.

The American Society of Clinical Oncology named Immunotherapy 2.0 as the Advance of the Year, as it continues to move the cancer field forward.

Feelings of depression can be overwhelming after a diagnosis of breast cancer, and shame is often attached to those feelings.

Three recent trials showed that Keytruda had a durable response for patients with a rare subtype of melanoma.

Jenny C. Chang, M.D., discusses the future of breast cancer care, and what role molecular testing will play.

Diagnostic laparoscopy can play a role in predicting surgery outcomes for patients with ovarian cancer.

Kim Johnson shares poetry from the night of her seizure and how much of a difference three years makes.

Patients with lung cancer do not receive supportive and survivorship care.

Symptoms like depression and fatigue can linger long after cancer treatment ends. Researchers at Duke created an online program to help survivors cope.

In a recent study, Abraxane (nab-paclitaxel) and carboplatin reduced risk of progression or death in patients with triple-negative breast cancer.

Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.

The Cancer Survivorship Symposium ended Saturday afternoon on a note of hope provided by survivor Wendy Harpham, M.D.

Despite recommendations to do so, distribution of survivorship care plans still has not increased for survivors of cancer, according to a recent study.

A recent study examined if the benefit from the drug brentuximab vedotin was worth the neuropathy that it causes for many patients with lymphoma.

Findings from a recent study lay out the groundwork to help identify men who are at higher risk from dying of prostate cancer.

Deborah K. Mayer recalls the breast cancer patient she counseled about treatment options.

It's my hope that two versions of the same story continue to be written because I am not ready to be the only storyteller.

Wanting to leave the world of cancer behind is a normal feeling for many touched by breast cancer.

The Life Raft Group, a patient advocacy organization, is teaming up with research organizations to hopefully find the next wave of treatment for patients with gastrointestinal stromal tumors.

As this weekend's Cancer Survivorship Symposium, the discussion focused on what survivors need, when and with whom,

As the needs of cancer survivors have been determined and researched, there is still confusion about which medical professional cares for what part of their survival.

CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.

Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.

From stigma to convenience, there are many reasons why people do not get the HPV vaccine, although it can prevent some types of cancer. Lois Ramondetta, M.D., discusses updated recommendations and hopes for getting more young people vaccinated.